A detailed history of J.Safra Asset Management Corp transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 43 shares of COGT stock, worth $199. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43
Holding current value
$199
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 25, 2025

BUY
$5.99 - $9.66 $257 - $415
43 New
43 $0

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $305M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track J.Safra Asset Management Corp Portfolio

Follow J.Safra Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J.Safra Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on J.Safra Asset Management Corp with notifications on news.